+1 (202) 780-3397
MEDICAL CANNABIS FOR AUTISM SPECTRUM DISORDER, IS IT AN OPTION?
2nd International Conference on PSYCHIATRY AND PSYCHOLOGICAL DISORDERS
May 20-21, 2019 | Rome, Italy
Joseph Rosado
International Medical Consultants, USA
Keynote : J Clin Psychiatry Cog Psychol
Abstract:
Objective: A literature review was conducted to evaluate the validity of medical
cannabis as an adjunctive treatment in the management of individuals
with autism spectrum disorders.
Background: Autism spectrum disorder (ASD) is a developmental disability
that can cause significant social, communication and behavioral challenges.
The learning, thinking and problem-solving abilities of people with ASD can
range from gifted to severely challenged people. Since there is no medical
test to diagnose the disorders, the provider must listen to the parent/caretaker
and look at the child’s behavior and development to make a diagnosis. Unfortunately,
many children do not receive a final diagnosis until much older.
A deficiency in the endocannabinoid system in the body is considered as the
reason for many disorders and recent researcher’s state that it might help in
the treatment of autism. The chronic neuro inflammation can be eased with
the help of the antioxidants which are present in the cannabis plant. The theory
of CED was based on the concept that many brain disorders are associated
with neurotransmitter deficiencies, affecting acetylcholine in Alzheimer’s
disease, dopamine in Parkinsonian syndromes, serotonin and norepinephrine
in depression and that a comparable deficiency in endocannabinoid levels
might be manifest similarly in certain disorders that display predictable
clinical features as sequelae of this deficiency.
Design & Methods: A literature review was conducted at the National Center
for Biotechnology Information, US National Library of Medicine PubMed
from 2012-2018 specific to the topic of medical cannabis and autism spectrum
disorder.
Conclusion: This literature review supports the feasibility of cannabis based
medicine as a promising treatment option in children with ASD. Based on the
promising results, it is recommended that large, double blind, placebo controlled
cross-over trials was launched in jurisdictions where medical cannabis
can be studied without limitations from the federal government.
Biography:
Joseph Rosado, after spending several years in central Florida working as an orderly, then an EMT/Paramedic and Heart cath lab technician, he realized his passion for the medical profession. He started chiropractic school at Life College in Marietta, GA where he graduated cum laude with a BS degree in Clinical Nutrition and a Doctor of Chiropractic Degree. After practicing for several years, he went on to Universidad Central del Este; in San Pedro de Macoris in 2001 he graduated summa cum laude with his medical degree. He completed his MBA in Health Care Management from University of Phoenix and graduated magna cum laude in 2005. He has worked as a Physician, Clinic and Hospital Director, Director of the Communicable Disease Division/Epidemiology and Immunization Departments. Currently he is the Medical Director of a Medical Cannabis Clinic, President/CEO of International Medical Consultants and volunteers once a month at a community clinic. He is on the bureau of speakers for political campaigns, cannabis advocacy and medical cannabis dispensaries in the United States, Canada, Mexico, Thailand and Colombia, as well as published multiple articles on the use of medical cannabis. He has worked with close to 2,000 patients, which include infants, toddlers, children, adolescents, adults and geriatrics for the evaluation, recommendation and management of medical cannabis till date.
E-mail: jrmddc@gmail.com
PDF HTML